Document Detail


Sustained long-term benefit of sildenafil in primary pulmonary hypertension.
MedLine Citation:
PMID:  17375892     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Primary pulmonary hypertension is a rare disease with an ominous prognosis for which new therapeutic options are being developed. Recently, there have been case reports indicating that sildenafil may be of benefit in short- to midterm follow-up. However, long-term clinical data of sildenafil in primary pulmonary hypertensive patients is lacking. We report a patient with primary pulmonary hypertension treated with sildenafil 200 mg/day for 50 months with a sustained clinical response.
Authors:
Tamer Sayin; Metin Ozenci
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Acta cardiologica     Volume:  62     ISSN:  0001-5385     ISO Abbreviation:  Acta Cardiol     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-03-22     Completed Date:  2007-04-24     Revised Date:  2009-06-11    
Medline Journal Info:
Nlm Unique ID:  0370570     Medline TA:  Acta Cardiol     Country:  Belgium    
Other Details:
Languages:  eng     Pagination:  47-9     Citation Subset:  IM    
Affiliation:
Ankara University, Department of Cardiology, Heart Center, Ankara, Turkey. tamsay@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Humans
Hypertension, Pulmonary / drug therapy*
Male
Phosphodiesterase Inhibitors / therapeutic use*
Piperazines / therapeutic use*
Prognosis
Purines / therapeutic use
Sulfones / therapeutic use*
Time Factors
Chemical
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 139755-83-2/sildenafil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is it possible to increase the diagnostic value of exercise electrocardiography by post-exercise B-t...
Next Document:  Systemic amyloidosis: a clinical challenge.